Delcath Systems

$15.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.44%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell DCTH and other stocks, options, and ETFs commission-free!

About DCTH

Delcath Systems, Inc. Common Stock, also called Delcath Systems, is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY. The listed name for DCTH is Delcath Systems, Inc. Common Stock.

CEO
Gerard J. Michel
Employees
33
Headquarters
New York, New York
Founded
1988
Market Cap
65.54M
Price-Earnings Ratio
0.21
Dividend Yield
Average Volume
158.53K
High Today
$16.16
Low Today
$15.51
Open Price
$16.14
Volume
56.35K
52 Week High
$35.00
52 Week Low
$5.15

Collections

DCTH Earnings

-$108.07
-$72.05
-$36.02
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 24, Pre-Market

You May Also Like